Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes (Diabetes Care, 2013. 36:2239-46)
{"Image DocumentName": "Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY , a Neutralizing IL-1\u03b2 Antibody, in Patients With Type 2 Diabetes (Diabetes Care, : )", "Image ImageDescription": "Placebo-corrected decrease in HbA1c of -0.27, and -0.25% for 0.6, 18 and 180 mg by end of treatment (week 12) Placebo-corrected decrease in HbA1c of -0.18, and -0.43% for 0.6, 18 and 180 mg by end of follow up (weak 24; sustained effect for 12 weeks) Patients achieving HbA1c < 7% 52.4, 31.3, and 26.3% for 0.6, 18, and 180 mg. Decreased postprandiale glucose. Enhanced insulin secretion. Reduction in CRP.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}